搜索
Repligen Corp
RGEN添加自选
106.990USD
-6.610-5.82%
收盘 05/13, 16:00（美东）报价延迟15分钟
6.03B总市值
117.13市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-5.82%
5天
-14.82%
1月
-10.92%
6月
-28.94%
今年开始到现在
-34.71%
1年
-19.99%
TradingKey Repligen Corp股票评分
单位: USD 更新时间: 2026-05-12操作建议
Repligen Corp当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在医疗设备与耗材行业排名18/206位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价182.17。中期看，股价处于下降通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Repligen Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Repligen Corp亮点
亮点风险
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
业绩高增长
公司营业收入稳步增长，连续3年增长16.75%
利润高增长
公司净利润处于行业前列，最新年度总收入738.26M美元
业绩转盈
公司业绩转盈，最新年度盈利美元
估值合理
公司最新PE估值124.36，处于3年历史合理位
机构减仓
最新机构持股65.93M股，环比减少3.85%
加拿大丰业银行分红基金持仓
明星投资者加拿大丰业银行分红基金持仓，最新持仓市值44.48K
活跃度增加
近期活跃度增加，过去20天平均换手率0.43
分析师目标
根据
22
位分析师
买入
评级
182.170
目标均价
+47.55%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Repligen Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Repligen Corp简介
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
公司代码RGEN
公司Repligen Corp
CEOLoeillot (Olivier)
网址https://www.repligen.com/
相关品种
+1.18%
-2.88%
+0.08%
-0.62%
+3.10%
-0.19%
+2.60%
-0.81%
-0.50%
+1.74%
+0.71%
-1.94%
-2.03%
+2.09%
-0.98%
-2.26%
+3.25%
-4.97%
+0.44%
-0.14%
